Browse by author
Lookup NU author(s): Mr. Guerra Guerra, Dr Moritz von Stosch, Professor Jarka Glassey
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.Biotherapeutics, such as those derived from monoclonal antibodies (mAbs), are industrially produced in controlled multiunit operation bioprocesses. Each unit operation contributes to the final characteristics of the bioproduct. The complexity of the bioprocesses, the cellular machinery, and the bioproduct molecules, typically leads to inherent heterogeneity and variability of the final critical quality attributes (CQAs). In order to improve process control and increase product quality assurance, online and real-time monitoring of product CQAs is most relevant. In this review, the recent advances in CQAs monitoring of biotherapeutic drugs, with emphasis on mAbs, and throughout, the different bioprocess unit operations are reviewed. Recent analytical techniques used for assessment of product-related CQAs of mAbs are considered in light of the analytical speed and ability to measure different CQAs. Furthermore, the state of art modeling approaches for CQA estimation in real-time are presented as a viable alternative for real-time bioproduct CQA monitoring under the process analytical technology and quality-by-design frameworks in the biopharmaceutical industry, which have recently been demonstrated.
Author(s): Guerra A, von Stosch M, Glassey J
Publication type: Review
Publication status: Published
Journal: Critical Reviews in Biotechnology
Year: 2019
Volume: 39
Issue: 3
Pages: 289-305
Online publication date: 06/02/2019
Acceptance date: 31/08/2018
ISSN (print): 0738-8551
ISSN (electronic): 1549-7801
Publisher: Taylor and Francis Ltd
URL: https://doi.org/10.1080/07388551.2018.1524362
DOI: 10.1080/07388551.2018.1524362
